Tags : P-III Checkmate-451 Study

Bristol-Myers’ Opdivo and Yervoy Combination Couldn’t Meet OS as Maintenance

Vartika Singh November 27, 2018

Shots: The P-III Checkmate-451 involves assessing Opdivo (nivolumab, 1mg/kg) + Yervoy (ipilimumab,3 mg/kg) vs PBO as a maintenance therapy in patients with extensive-stage small cell lung cancer (SCLC) The study […]readmore

Tags : P-III Checkmate-451 Study

Bristol-Myers’ Opdivo and Yervoy Combination Couldn’t Meet OS as Maintenance

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : P-III Checkmate-451 Study

Bristol-Myers’ Opdivo and Yervoy Combination Couldn’t Meet OS as Maintenance

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company